Sarepta Therapeutics (SRPT) said Wednesday that early clinical results showed that its investigational siRNA treatments SRP-1001 and SRP-1003 achieved high muscle concentrations in patients with neuromuscular diseases.
SRP-1001 and SRP-1003 demonstrated dose-dependent muscle exposure, early biomarker effects, and favorable tolerability in patients with facioscapulohumeral muscular dystrophy type 1 and myotonic dystrophy type 1, respectively, the company said.
In both phase 1/2 ascending dose studies, the majority of adverse events were mild to moderate and were not dose dependent, Sarepta said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments